BSE Live
Nov 07, 16:01Prev. Close
1205.05
Open Price
1209.45
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Nov 07, 15:58Prev. Close
1205.20
Open Price
1208.00
Bid Price (Qty.)
1205.40 (1249)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Dr Reddys Laboratories (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 2,059.90 | 2,454.40 | 1,753.20 | 1,259.20 | 1,051.90 | |
| Net CashFlow From Operating Activities | 1,786.10 | 905.50 | 288.80 | 1,402.90 | 246.30 | |
| Net Cash Used In Investing Activities | -2,016.50 | -880.80 | -518.90 | -423.50 | -613.00 | |
| Net Cash Used From Financing Activities | 189.40 | 28.20 | 151.80 | -194.80 | 61.00 | |
| Foreign Exchange Gains / Losses | -14.60 | 6.60 | -5.60 | -1.80 | 3.90 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -55.60 | 59.50 | -83.90 | 782.80 | -301.80 | |
| Cash And Cash Equivalents Begin of Year | 115.60 | 56.10 | 140.00 | 66.20 | 368.00 | |
| Cash And Cash Equivalents End Of Year | 60.00 | 115.60 | 56.10 | 849.00 | 66.20 |
28.10.2025
Dr Reddys Labs Consolidated September 2025 Net Sales at Rs 8,828.30 crore, up 9.83% Y-o-Y
28.10.2025
Dr Reddys Labs Standalone September 2025 Net Sales at Rs 4,618.60 crore, down 31.03% Y-o-Y
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
24.07.2025
Dr Reddys Labs Standalone June 2025 Net Sales at Rs 7,809.50 crore, up 33.7% Y-o-Y
22.01.2025
Dr Reddy's Labs Q3 Preview: Lower Revlimid contribution, subdued US sales to dent earnings growth
12.07.2023
Dr Reddys Laboratories Q1 PAT seen up 73.7% YoY to Rs 912.4 cr: Nirmal Bang
24.01.2023
Dr Reddy’s Q3 Preview | Sharp drop in net profit likely on slump in US revenues
27.10.2022
Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop in net profit on weak US biz